Search - tctmd.com

Displaying 441 - 460 of 646

Sort: Relevancy | Date

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Industry News

U.S. to vie with India for top bioabsorbable stent market after FDA approval

June 25, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

FDA approves new antiplatelet drug used during heart procedure

June 24, 2015

News Daily News

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Todd Neale

June 22, 2015

News Daily News

Possible Cardiovascular Risk of PPIs Lingers in 2 New Studies

June 18, 2015

News Daily News

Meta-analysis Confirms Late Safety of Second-Generation DES

L.A. McKeown

June 10, 2015

News Daily News

Meta 分析证实了第二代 DES 的晚期安全性

L.A. McKeown

June 10, 2015

News Industry News

Early Healing Profile Established for BioFreedom

May 20, 2015

News Daily News

TAVR后阿司匹林单药疗法的疗效不比DAPT差，可能更安全

May 14, 2015

News Daily News

Post-TAVR Aspirin Monotherapy No Less Effective, Possibly Safer Than DAPT

May 14, 2015

News Daily News

Ticagrelor More Rapidly Suppresses Platelet Activity Than Clopidogrel for Low-Risk ACS Patients During Ad Hoc PCI

Todd Neale

May 11, 2015

News Daily News

双联抗血小板治疗与高危PAD患者的更佳结果有联系

Leah Lawrence

April 29, 2015

News Daily News

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

April 29, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

News Daily News

El Tratamiento Antiplaquetario Doble se asoció a Mejores Resultados en Pacientes EAP de Alto Riesgo

Leah Lawrence

April 29, 2015

News Daily News

Dual Antiplatelet Therapy Tied to Better Outcomes in High Risk PAD Patients

Leah Lawrence

April 29, 2015

Advertisement

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

U.S. to vie with India for top bioabsorbable stent market after FDA approval

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

FDA approves new antiplatelet drug used during heart procedure

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Possible Cardiovascular Risk of PPIs Lingers in 2 New Studies

Meta-analysis Confirms Late Safety of Second-Generation DES

Meta 分析证实了第二代 DES 的晚期安全性

Early Healing Profile Established for BioFreedom

TAVR后阿司匹林单药疗法的疗效不比DAPT差，可能更安全

Post-TAVR Aspirin Monotherapy No Less Effective, Possibly Safer Than DAPT

Ticagrelor More Rapidly Suppresses Platelet Activity Than Clopidogrel for Low-Risk ACS Patients During Ad Hoc PCI

双联抗血小板治疗与高危PAD患者的更佳结果有联系

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

El Tratamiento Antiplaquetario Doble se asoció a Mejores Resultados en Pacientes EAP de Alto Riesgo

Dual Antiplatelet Therapy Tied to Better Outcomes in High Risk PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content